Apyx Medical Corp (APYX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 20M 40M 60M FY09: 27M FY10: 24.2M FY11: 25.4M FY12: 27.7M FY13: 23.7M FY14: 27.7M FY15: 29.5M FY16: 8.8M FY17: 10.2M FY18: 16.6M FY19: 28.2M FY20: 27.7M FY21: 48.5M FY22: 44.5M FY23: 52.3M FY24: 48.1M FY25: 52.8M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 15M 30M 45M FY09: 11.9M FY10: 10M FY11: 10.7M FY12: 11.3M FY13: 9.2M FY14: 9M FY15: 12.6M FY16: 5.1M FY17: 7M FY18: 10.8M FY19: 19.1M FY20: 17.5M FY21: 33.6M FY22: 29.1M FY23: 33.8M FY24: 29.4M FY25: 33M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating Income Annual

-27M -18M -9M 0 9M 18M 27M FY09: 715K FY10: -2.8M FY11: -18K FY12: 1M FY13: -3.7M FY14: -5.8M FY15: -7M FY16: -11.4M FY17: -13.9M FY18: -14.3M FY19: -20.9M FY20: -20.1M FY21: -14.4M FY22: -23.6M FY23: -17.3M FY24: -18.8M FY25: -6.4M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-25M 0 25M 50M 75M FY09: 596K FY10: -1.5M FY11: 109K FY12: 617K FY13: -4.3M FY14: -17.3M FY15: -5.4M FY16: -11.6M FY17: -5.1M FY18: 62.7M FY19: -19.7M FY20: -11.9M FY21: -15.2M FY22: -23.2M FY23: -18.7M FY24: -23.5M FY25: -11.2M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 7M 14M 21M FY09: 15.1M FY10: 14.2M FY11: 14.7M FY12: 16.3M FY13: 14.5M FY14: 18.7M FY15: 17M FY16: 3.7M FY17: 3.3M FY18: 5.8M FY19: 9.1M FY20: 10.2M FY21: 14.9M FY22: 15.4M FY23: 18.6M FY24: 18.7M FY25: 19.8M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating Cash Flow Annual

-24M -16M -8M 0 8M 16M 24M FY09: -97K FY10: -526K FY11: 1.9M FY12: 165K FY13: -2.5M FY14: -417K FY15: -5.8M FY16: -2.8M FY17: -3.7M FY18: -20.9M FY19: -18.5M FY20: -16.1M FY21: -10.4M FY22: -20.3M FY23: -5.2M FY24: -18M FY25: -8M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-24M -16M -8M 0 8M 16M 24M FY09: -2.6M FY10: -727K FY11: 1.4M FY12: -588K FY13: -3.1M FY14: -1M FY15: -6.2M FY16: -3.1M FY17: -4.3M FY18: -21.2M FY19: -19.8M FY20: -16.6M FY21: -11.2M FY22: -21.3M FY23: -5.8M FY24: -18.8M FY25: -9.1M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 15M 30M 45M FY09: 16.9M FY10: 17.4M FY11: 17.7K FY12: 17.8K FY13: 17.8M FY14: 17.8M FY15: 27.7M FY16: 27.4M FY17: 31.4M FY18: 34.4M FY19: 34.1M FY20: 34.2M FY21: 34.3M FY22: 34.5M FY23: 34.6M FY24: 35.5M FY25: 41.1M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-105.00 -70.00 -35.00 0.00 35.00 70.00 105.00 Q4 '10: -0.09 Q1 '12: -0.02 Q3 '16: -0.18 Q4 '16: -0.15 Q1 '17: -0.14 Q2 '17: -0.16 Q3 '17: -0.16 Q4 '17: -0.17 Q1 '18: -0.14 Q2 '19: -98.34 Q3 '19: -100.43 Q4 '19: -0.59 Q1 '20: -0.48 Q2 '20: -0.49 Q3 '20: -0.47 Q4 '20: -0.36 Q1 '21: -0.44 Q2 '21: -0.42 Q3 '21: -0.43 Q4 '21: -0.44 Q1 '22: -0.47 Q2 '22: -0.51 Q3 '22: -0.56 Q4 '22: -0.67 Q1 '23: -0.60 Q2 '23: -0.47 Q3 '23: -0.43 Q4 '23: -0.54 Q1 '24: -0.66 Q2 '24: -0.82 Q3 '24: -0.83 Q4 '24: -0.67 Q1 '25: -0.55 Q2 '25: -0.45 Q3 '25: -0.36 Q4 '25: -0.27 Q1 '26: -0.22 Q2 '26: -0.20 Q3 '16 Q4 '17 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.